Literature DB >> 23580589

FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.

Xiang Tao1, Naiqing Zhao, Hongyan Jin, Zhenbo Zhang, Yintao Liu, Jian Wu, Robert C Bast, Yinhua Yu, Youji Feng.   

Abstract

Recent studies have suggested that FSH plays an important role in ovarian epithelial carcinogenesis. We demonstrated that FSH stimulates the proliferation and invasion of ovarian cancer cells, inhibits apoptosis and facilitates neovascularisation. Our previous work has shown that transient receptor potential channel C3 (TRPC3) contributes to the progression of human ovarian cancer. In this study, we further investigated the interaction between FSH and TRPC3. We found that FSH stimulation enhanced the expression of TRPC3 at both the mRNA and protein levels. siRNA-mediated silencing of TRPC3 expression inhibited the ability of FSH to stimulate proliferation and blocked apoptosis in ovarian cancer cell lines. FSH stimulation was associated with the up-regulation of TRPC3, while also facilitating the influx of Ca(2)(+) after treatment with a TRPC-specific agonist. Knockdown of TRPC3 abrogated FSH-stimulated Akt/PKB phosphorylation, leading to decreased expression of downstream effectors including survivin, HIF1-α and VEGF. Ovarian cancer specimens were analysed for TRPC3 expression; higher TRPC3 expression levels correlated with early relapse and worse prognosis. Association with poor disease-free survival and overall survival remained after adjusting for clinical stage and grade. In conclusion, TRPC3 plays a significant role in the stimulating activity of FSH and could be a potential therapeutic target for the treatment of ovarian cancer, particularly in postmenopausal women with elevated FSH levels.

Entities:  

Keywords:  cell proliferation; follicle-stimulating hormone (FSH); ovarian epithelial cancer; prognosis; transient receptor potential channel C3 (TRPC3)

Mesh:

Substances:

Year:  2013        PMID: 23580589      PMCID: PMC3669658          DOI: 10.1530/ERC-12-0005

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  41 in total

1.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Authors:  Y L Hu; M K Tee; E J Goetzl; N Auersperg; G B Mills; N Ferrara; R B Jaffe
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

2.  Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells.

Authors:  Young-Han Park; Su Jin Kim; Byung-Hoon Jeong; Thomas J Herzog; Jason Wright; Jan Kitajewski; Chae Chun Rhim; Pong Rheem Jang; Jung Bae Kang; Sung Ju Kim
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

Review 3.  Loss of ovarian function and the risk of ovarian cancer.

Authors:  Barbara C Vanderhyden
Journal:  Cell Tissue Res       Date:  2005-11-03       Impact factor: 5.249

4.  Hypoxia differentially regulates the mitogen- and stress-activated protein kinases. Role of Ca2+/CaM in the activation of MAPK and p38 gamma.

Authors:  P W Conrad; D E Millhorn; D Beitner-Johnson
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

5.  Essential role of TRPC6 channels in G2/M phase transition and development of human glioma.

Authors:  Xia Ding; Zhuohao He; Kechun Zhou; Ju Cheng; Hailan Yao; Dongliang Lu; Rong Cai; Yening Jin; Bin Dong; Yinghui Xu; Yizheng Wang
Journal:  J Natl Cancer Inst       Date:  2010-06-16       Impact factor: 13.506

6.  Coupling of mitochondria to store-operated Ca(2+)-signaling sustains constitutive activation of protein kinase B/Akt and augments survival of malignant melanoma cells.

Authors:  Ben Feldman; Shlomit Fedida-Metula; Julia Nita; Israel Sekler; Daniel Fishman
Journal:  Cell Calcium       Date:  2010-06-01       Impact factor: 6.817

7.  Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Rudolf Kaaks; Sabina Rinaldi; Kathy J Helzlsouer
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

8.  Early-stage morphological observations of myoma and myometrium after laparoscopic uterine artery occlusion treatment.

Authors:  Zhong-Ping Cheng; Xiang Tao; Jun Gong; Hong Dai; Li-Ping Hu; Wei-Hong Yang
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2009-05-17       Impact factor: 2.435

9.  Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation.

Authors:  Yassine El Hiani; Ahmed Ahidouch; V'yacheslav Lehen'kyi; Frédéric Hague; Fabrice Gouilleux; Romuald Mentaverri; Said Kamel; Kaiss Lassoued; Gérard Brûlé; Halima Ouadid-Ahidouch
Journal:  Cell Physiol Biochem       Date:  2009-05-06

10.  Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women.

Authors:  Alan A Arslan; Anne Zeleniuch-Jacquotte; Eva Lundin; Andrea Micheli; Annekatrin Lukanova; Yelena Afanasyeva; Per Lenner; Vittorio Krogh; Paola Muti; Sabina Rinaldi; Rudolf Kaaks; Franco Berrino; Göran Hallmans; Paolo Toniolo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-12       Impact factor: 4.254

View more
  15 in total

Review 1.  Role of TRP ion channels in cancer and tumorigenesis.

Authors:  George Shapovalov; Abigael Ritaine; Roman Skryma; Natalia Prevarskaya
Journal:  Semin Immunopathol       Date:  2016-02-03       Impact factor: 9.623

2.  Expression of canonical transient receptor potential channels in U-2 OS and MNNG-HOS osteosarcoma cell lines.

Authors:  Florian Lässig; Anja Klann; Sander Bekeschus; Uwe Lendeckel; Carmen Wolke
Journal:  Oncol Lett       Date:  2021-02-21       Impact factor: 2.967

3.  Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.

Authors:  Kazuhisa Hagiwara; Takuya Koie; Chikara Ohyama; Hayato Yamamoto; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Yuki Tobisawa; Tohru Yoneyama
Journal:  Int Urol Nephrol       Date:  2017-02-17       Impact factor: 2.370

4.  Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.

Authors:  Mingzhu Bai; Linlin Yang; Hong Liao; Xiaoyan Liang; Bingying Xie; Ji Xiong; Xiang Tao; Xiong Chen; Yali Cheng; Xiaojun Chen; Youji Feng; Zhenbo Zhang; Wenxin Zheng
Journal:  Oncogene       Date:  2018-06-19       Impact factor: 9.867

5.  Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

Authors:  J Chen; M Bai; C Ning; B Xie; J Zhang; H Liao; J Xiong; X Tao; D Yan; X Xi; X Chen; Y Yu; R C Bast; Z Zhang; Y Feng; W Zheng
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

6.  Leptin OB3 peptide suppresses leptin-induced signaling and progression in ovarian cancer cells.

Authors:  Yu-Tang Chin; Le-Ming Wang; Meng-Ti Hsieh; Ya-Jung Shih; André Wendindondé Nana; Chun A Changou; Yu-Chen S H Yang; Hsien-Chung Chiu; Earl Fu; Paul J Davis; Heng-Yuan Tang; Hung-Yun Lin
Journal:  J Biomed Sci       Date:  2017-07-27       Impact factor: 8.410

7.  FSH receptor binding inhibitor impacts K-Ras and c-Myc of ovarian cancer and signal pathway.

Authors:  Suocheng Wei; Xiaoyun Shen; Luju Lai; Haoqin Liang; Yingying Deng; Zhuandi Gong; Tuanjie Che
Journal:  Oncotarget       Date:  2018-04-27

Review 8.  The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis.

Authors:  Megan M Emori; Ronny Drapkin
Journal:  Reprod Biol Endocrinol       Date:  2014-07-06       Impact factor: 5.211

9.  Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.

Authors:  Yiying Wang; Yue Wang; Zhenbo Zhang; Ji-Young Park; Donghui Guo; Hong Liao; Xiaofang Yi; Yu Zheng; Donna Zhang; Setsuko K Chambers; Wenxin Zheng
Journal:  Oncotarget       Date:  2016-03-01

Review 10.  Calcium Permeable Channels in Cancer Hallmarks.

Authors:  Sendoa Tajada; Carlos Villalobos
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.